PROTAGONIST THERAPEUTICS, INC.

(PTGX)
  Report
Delayed Nasdaq  -  04:00 2022-06-28 pm EDT
8.450 USD   -7.35%
06/24PROTAGONIST THERAPEUTICS, INC.(NASDAQGM : PTGX) dropped from Russell 2500 Growth Index
CI
06/24PROTAGONIST THERAPEUTICS, INC.(NASDAQGM : PTGX) dropped from Russell 3000 Growth Index
CI
06/24PROTAGONIST THERAPEUTICS, INC.(NASDAQGM : PTGX) added to Russell Microcap Value Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Piper Sandler Adjusts Price Target on Protagonist Therapeutics to $35 From $60, Reiterates Overweight Rating

05/18/2022 | 06:53am EDT


© MT Newswires 2022
All news about PROTAGONIST THERAPEUTICS, INC.
06/24PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) dropped from Russell 2500 Growth Index
CI
06/24PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) dropped from Russell 3000 Growth Index
CI
06/24PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) added to Russell Microcap Value Index
CI
06/24PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) added to Russell Small Cap Comp Value Index
CI
06/24PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) added to Russell 2000 Value Index
CI
06/24PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) dropped from Russell Small Cap Comp Growth In..
CI
06/24PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) dropped from Russell 2000 Growth Index
CI
06/24PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) added to Russell 3000 Value Index
CI
06/24PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) added to Russell 3000E Value Index
CI
06/24PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) dropped from Russell 3000E Growth Index
CI
More news
Analyst Recommendations on PROTAGONIST THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 31,9 M - -
Net income 2022 -157 M - -
Net cash 2022 174 M - -
P/E ratio 2022 -2,67x
Yield 2022 -
Capitalization 411 M 411 M -
EV / Sales 2022 7,43x
EV / Sales 2023 29,8x
Nbr of Employees 122
Free-Float 98,6%
Chart PROTAGONIST THERAPEUTICS, INC.
Duration : Period :
Protagonist Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROTAGONIST THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 8,45 $
Average target price 40,00 $
Spread / Average Target 373%
EPS Revisions
Managers and Directors
Dinesh V. Patel President, Chief Executive Officer & Director
Asif Ali Chief Financial Officer & Executive Vice President
Harold E. Selick Chairman
Mark L. Smythe Vice President-Technology
David Y. Liu Chief Research & Development Strategy Officer
Sector and Competitors
1st jan.Capi. (M$)
PROTAGONIST THERAPEUTICS, INC.-75.29%411
MODERNA, INC.-44.02%57 385
IQVIA HOLDINGS INC.-24.79%40 468
LONZA GROUP AG-32.64%39 851
SEAGEN INC.15.44%33 010
CELLTRION, INC.-11.87%18 371